New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 21, 2014
09:13 EDTTGT, TSL, INTU, CMRX, ST, EBAY, AEO, PETM, TIF, CRMOn The Fly: Pre-market Movers
HIGHER: Tiffany (TIF), up 7% after reporting earnings, raising its fiscal year profit view... Target (TGT), up 0.7% after reporting better than expected adjusted earnings, cutting its adjusted earning per share outlook... Trina Solar (TSL), up 10.7% following better than expected earnings... Chimerix (CMRX), up 2% after its 7.3M share secondary stock offering priced at $14.22 per share. LOWER: PetSmart (PETM), down 7% after quarterly and fiscal year profit guidance misses consensus view... Intuit (INTU), down 5.3% after reporting third quarter results and providing fourth quarter guidance below analyst estimates... American Eagle (AEO), down 3.6% after quarterly earnings view below consensus, says will close additional stores... salesforce.com (CRM), down 1% despite raising guidance for fiscal 2015... eBay (EBAY), down 1.6% after disclosing cyberattack, asking user to change passwords... Sensata (ST), down 1.6% after its 11.5M share secondary stock offering priced at $42.65 per share.
News For TGT;TIF;PETM;AEO;EBAY;ST;CMRX;INTU;TSL;CRM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>
October 9, 2014
09:38 EDTEBAYActive equity options trading on open
Subscribe for More Information
08:01 EDTTGTTarget CEO hands-on with Canadian turnaround, Globe and Mail says
Brian Cornell, the new CEO of Target, told The Globe and Mail in an interview that he is taking a hands-on approach to repairing the company’s Canadian business and that he will travel north on a “regular” basis to oversee the turnaround. Reference Link
07:34 EDTCRMSalesforce.com coverage assumed with a Buy at MKM Partners
Subscribe for More Information
October 8, 2014
16:26 EDTEBAYOn The Fly: Closing Wrap
Subscribe for More Information
12:41 EDTEBAYeBay ChannelAdvisor data confirms company guidance, says Piper Jaffray
Piper Jaffray noted ChannelAdvisor reported eBay's same-store sales grew 8.9% in September, which confirms the company's reiterated guidance when it announced its planned PayPal spin-off. The firm maintains its Neutral rating on eBay.
12:25 EDTCMRXOn The Fly: Midday Wrap
Subscribe for More Information
12:09 EDTINTUIntuit management to meet with Oppenheimer
Subscribe for More Information
12:01 EDTCMRXChimerix plunges after first U.S. Ebola patient dies, levels to watch
The shares are down 11.5% to $29.38 following news that the first U.S. Ebola patient, Thomas Eric Duncan, has died. Duncan was being treated with the company's experimental Ebola drug, Brincidofovir. Based on current price, next support is at $27.62. Resistance is at $30.06 and then at $30.70.
11:55 EDTCMRXChimerix options active after Ebola patient taking experimental drug dies
Subscribe for More Information
11:52 EDTCMRXChimerix shares to be volatile as stock tracks Ebola news, says Piper Jaffray
Piper Jaffray noted the move lower in Chimerix following news that a patient in Texas that was being treated with its brincidofovir drug has died and said the stock will now be in a "much more volatile position" as its movements track news on the Ebola outbreak and treated patients. The firm believes the drug's usefulness in treating Ebola will need to be defined by more data and trials and that its established utility in other diseases provides value above the stock's current levels. Piper maintains its Overweight rating on shares of Chimerix.
11:22 EDTCMRXChimerix falls after Ebola patient taking experimental drug dies
Shares of Chimerix (CMRX) are moving lower after the Texas Health Presbyterian Hospital Dallas announced that Thomas Eric Duncan succumbed to Ebola. Duncan was being treated with Chimerix's experimental drug Brincidofovir. Shares of Chimerix dropped 9% following the news to $30.19. Other makers of experimental Ebola treatments include Tekmira (TKMR), Sarepta (SRPT) and BioCryst (BCRX).
11:17 EDTCMRXChimerix down 4% after Texas Ebola patient dies
Subscribe for More Information
10:18 EDTCMRXChimerix price target raised to $47 from $34 at Stifel
Subscribe for More Information
09:53 EDTCMRXChimerix price target raised to $41 from $37 at Piper Jaffray
Subscribe for More Information
09:42 EDTEBAYeBay SSS rose 8.9% in September, Amazon SSS up 37.9%, ChannelAdvisor says
Amazon's (AMZN) September SSS rose 37.9%, a decrease compared to August's 45.1%, ChannelAdvisor reported. eBay's (EBAY) September came in at 8.9% up from August's 5.9%, but below the e-commerce growth rate. "This is the first up-tick in eBay SSS since June and indicates that eBay is recovering from the breach and Google issues," ChannelAdvisor stated. Reference Link
09:20 EDTCMRXOn The Fly: Pre-market Movers
Subscribe for More Information
08:10 EDTEBAYeBay survey suggests upswing in growth, says RW Baird
Subscribe for More Information
06:36 EDTCMRXChimerix's Brincidofovir for adenovirus shows positive Phase 3 survival results
Chimerix announced preliminary data for its investigational antiviral brincidofovir showing improved survival for patients with adenovirus in the open-label pilot portion of the Phase 3 AdVise Trial. The preliminary survival analysis data showed a mortality rate of 35% vs. historic rates of up to 80% mortality in the first month after diagnosis. A majority of subjects also had suppression or clearance of adenovirus from the blood. There is currently no approved treatment for adenovirus. The safety and tolerability profile of brincidofovir in these initial subjects was similar to other studies of brincidofovir in immunocompromised patients with complicated medical issues, with only three subjects discontinuing due to adverse events.
October 7, 2014
13:28 EDTCMRXTekmira down 5% after report says Chimerix drug used on NBC journalist
Subscribe for More Information
13:13 EDTCMRXChimerix Ebola drug being used to treat U.S. patient in Nebraska, CNBC reports
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use